Your browser doesn't support javascript.
loading
Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.
Malewana, R Dilshan; Stalls, Victoria; May, Aaron; Lu, Xiaozhi; Martinez, David R; Schäfer, Alexandra; Li, Dapeng; Barr, Maggie; Sutherland, Laura L; Lee, Esther; Parks, Robert; Beck, Whitney Edwards; Newman, Amanda; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; DeMarco, C Todd; Denny, Thomas N; Oguin, Thomas H; Rountree, Wes; Wang, Yunfei; Mansouri, Katayoun; Edwards, Robert J; Sempowski, Gregory D; Eaton, Amanda; Muramatsu, Hiromi; Henderson, Rory; Tam, Ying; Barbosa, Christopher; Tang, Juanjie; Cain, Derek W; Santra, Sampa; Moore, Ian N; Andersen, Hanne; Lewis, Mark G; Golding, Hana; Seder, Robert; Khurana, Surender; Montefiori, David C; Pardi, Norbert; Weissman, Drew; Baric, Ralph S; Acharya, Priyamvada; Haynes, Barton F; Saunders, Kevin O.
Afiliação
  • Malewana RD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Stalls V; Department of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.
  • May A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Lu X; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Martinez DR; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Schäfer A; Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
  • Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Barr M; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Sutherland LL; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lee E; Department of Immunobiology, Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
  • Parks R; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Beck WE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Newman A; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bock KW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Minai M; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Nagata BM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • DeMarco CT; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Denny TN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Oguin TH; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Wang Y; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Mansouri K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Edwards RJ; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Sempowski GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Eaton A; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Muramatsu H; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
  • Henderson R; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
  • Tam Y; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA.
  • Barbosa C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Tang J; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Cain DW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Santra S; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Moore IN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Andersen H; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Lewis MG; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Golding H; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Seder R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Khurana S; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Pardi N; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Weissman D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Baric RS; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Acharya P; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Haynes BF; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
bioRxiv ; 2023 Dec 19.
Article em En | MEDLINE | ID: mdl-38187726
ABSTRACT
Immunization with mRNA or viral vectors encoding spike with diproline substitutions (S-2P) has provided protective immunity against severe COVID-19 disease. How immunization with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike elicits neutralizing antibodies (nAbs) against difficult-to-neutralize variants of concern (VOCs) remains an area of great interest. Here, we compare immunization of macaques with mRNA vaccines expressing ancestral spike either including or lacking diproline substitutions, and show the diproline substitutions were not required for protection against SARS-CoV-2 challenge or induction of broadly neutralizing B cell lineages. One group of nAbs elicited by the ancestral spike lacking diproline substitutions targeted the outer face of the receptor binding domain (RBD), neutralized all tested SARS-CoV-2 VOCs including Omicron XBB.1.5, but lacked cross-Sarbecovirus neutralization. Structural analysis showed that the macaque broad SARS-CoV-2 VOC nAbs bound to the same epitope as a human broad SARS-CoV-2 VOC nAb, DH1193. Vaccine-induced antibodies that targeted the RBD inner face neutralized multiple Sarbecoviruses, protected mice from bat CoV RsSHC014 challenge, but lacked Omicron variant neutralization. Thus, ancestral SARS-CoV-2 spike lacking proline substitutions encoded by nucleoside-modified mRNA can induce B cell lineages binding to distinct RBD sites that either broadly neutralize animal and human Sarbecoviruses or recent Omicron VOCs.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article